摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-甲氧基苄基氯甲基酮 | 24253-13-2

中文名称
4-甲氧基苄基氯甲基酮
中文别名
——
英文名称
4-methoxybenzylchloromethyl ketone
英文别名
1-chloro-3-(4-methoxy-phenyl)-propan-2-one;1-chloro-3-(4-methoxy-phenyl)-acetone;1-Chlor-3-(4-methoxy-phenyl)-aceton;1-chloro-3-(4-methoxyphenyl)propan-2-one;1-Chlor-3--propanon-(2);1-Chlor-3-<4-methoxy-phenyl>-propan-2-on
4-甲氧基苄基氯甲基酮化学式
CAS
24253-13-2
化学式
C10H11ClO2
mdl
——
分子量
198.649
InChiKey
NERHZTFDMOMRHP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    291.7±20.0 °C(Predicted)
  • 密度:
    1.159±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-甲氧基苄基氯甲基酮硫酸potassium carbonate 作用下, 生成 1-(3',5'-Dimethoxy-phenoxy)-3-(p-methoxy-phenyl)-aceton cyanhydrin
    参考文献:
    名称:
    Chatterjea,J.N. et al., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1979, vol. 17B, p. 42 - 44
    摘要:
    DOI:
  • 作为产物:
    描述:
    参考文献:
    名称:
    Pfeiffer; Bauer, Chemische Berichte, 1947, vol. 80, p. 7,18
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
    申请人:Weinstein David S.
    公开号:US20090075995A1
    公开(公告)日:2009-03-19
    Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R 5 , R 6 , R 7 , and R 8 ; J 1 , J 2 , and J 3 are at each occurrence the same or different and are independently -A 1 QA 2 -; Q is a bond, O, S, S(O), or S(O) 2 ; A 1 and A 2 are the same or different and are at each occurrence independently selected from a bond, C 1-3 alkylene, substituted C 1-3 alkylene, C 2-4 alkenylene, and substituted C 2-4 alkenylene, provided that A 1 and A 2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R 1 to R 11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.
    提供了一系列新颖的非甾体化合物,这些化合物在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中很有用,包括炎性和免疫疾病,具有以下结构式(I): 其对应的光学异构体、对映异构体或互变异构体,或其前药酯,或其药用可接受盐,其中: Z是杂环或杂芳基; A是一个5至8成员的碳环或一个5至8成员的杂环; B是一个环烷基、环烯基、芳基、杂环或杂芳基环,其中每个环都与A环上的相邻原子融合,并且可以选择性地被一个到四个独立选自R5、R6、R7和R8的相同或不同的组取代; J1、J2和J3每次出现时相同或不同,独立地选自-A1QA2-;Q是键、O、S、S(O)或S(O)2;A1和A2相同或不同,每次出现时独立地选自键、C1-3烷基、取代的C1-3烷基、C2-4烯基和取代的C2-4烯基,前提是A1和A2的选择使得环A是一个5至8成员的碳环或杂环; R1至R11如本文所述定义。 还提供了使用这些化合物的药物组合物和治疗炎性疾病、免疫相关疾病、肥胖和糖尿病的方法。
  • Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    申请人:Sheppeck James
    公开号:US20060154973A1
    公开(公告)日:2006-07-13
    The present invention relates to new class of non-steroidal compounds which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory- and immune-associated diseases, and have the structure including all stereoisomers thereof, tautomers thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein X is selected from N, O, and S; Y is N or CR 6 ; Z is a ring; and where R, R a , R b , R c , R d , R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    本发明涉及一类新的非甾体化合物,用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病,包括肥胖、糖尿病、炎症和免疫相关疾病,并具有结构,包括其所有立体异构体、互变异构体或前药,或其药用可接受盐,其中X选自N、O和S;Y为N或CR6;Z为一个环;R、Ra、Rb、Rc、Rd、R1、R2、R3、R4和R5如本文所定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
  • N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES
    申请人:GRIFFIOEN Gerard
    公开号:US20100197703A1
    公开(公告)日:2010-08-05
    This invention provides thiazolylpiperazine derivatives, and N-sulfonyl heterocyclic derivatives including phenyl- and benzyl-thiazolylpiperidine derivatives, and pharmaceutically acceptable salts thereof, which are useful active ingredients for administration in a method for the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides methods for making such derivatives, and pharmaceutical compositions including such derivatives together with pharmaceutically acceptable excipients.
    该发明提供了噻唑基哌嗪衍生物,以及包括苯基和苄基噻唑基哌啶衍生物的N-磺酰杂环衍生物,以及其药学上可接受的盐,这些是用于治疗α-突触核蛋白病的有效活性成分,如帕金森病、弥漫性小体病、创伤性脑损伤、肌萎缩侧索硬化症、尼曼-匹克病、哈勒沃登-施帕茨综合征、唐氏综合征、神经轴突萎缩、多系统萎缩和阿尔茨海默病的治疗方法。该发明还提供了制备这些衍生物的方法,以及包括这些衍生物和药学上可接受的辅料的药物组合物。
  • [EN] HETEROCYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF<br/>[FR] MODULATEURS HETEROCYCLIQUES DU RECEPTEUR GLUCOCORTICOIDE AP-1, ET/OU ACTIVITE NF-20050811US5569655ADORITY JR JOHN A [US], et al19961029AASee references of EP 1711488A4
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2005073221A1
    公开(公告)日:2005-08-11
    Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of Formula (I) or stereoisomers or prodrugs or solvates or pharmaceutically acceptable salts thereof, wherein A, B, J, K, Z, R, Ra, Rb, Rc, and Rd, are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    提供了一种新型的非甾体化合物,可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病,包括肥胖、糖尿病、炎症和免疫性疾病,并具有如下结构的化学式(I)或其立体异构体、前药、溶剂合物或其药用可接受的盐,其中A、B、J、K、Z、R、Ra、Rb、Rc和Rd在此有所定义。还提供了包含该化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
  • Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof
    申请人:Weinstein S. David
    公开号:US20050187242A1
    公开(公告)日:2005-08-25
    Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein B, J, K, Z, R, R a , R b , R c , R d , R q , R w , m and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
    提供了一种新型的非甾体化合物,可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病,包括肥胖、糖尿病、炎症和免疫性疾病,并具有以下结构的化学式(I)或其立体异构体或前药或其药用可接受盐,其中B、J、K、Z、R、Ra、Rb、Rc、Rd、Rq、Rw、m和n在此处被定义。还提供了包含所述化合物的药物组合物和治疗肥胖、糖尿病以及炎症或免疫相关疾病的方法。
查看更多